[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gait-disorders-neurologic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gait-disorders-neurologic":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,43,80,108,137,194,230,270,302,330,354,375,402,432,453,476,504,573,599,621,646,673,696],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053535","influence-of-hawthorne-effect-and-dual-tasks-on-gait-in-cp-100053535",false,"NCT05417399","Influence of Hawthorne Effect and Dual-tasks on Gait in CP","Ecological Validity of Clinical Gait Analysis in Children With Cerebral Palsy: Influence of the Hawthorne Effect and Dual-tasks. A Pilot Study","Inclusion Criteria:\n\n* Cerebral palsy, bilateral spastic, GMFCS classification I-III\n* Age \\\u003C16 years\n* Use of bilateral AFO's (rigid or ground reaction AFO's) to improve knee extension in stance\n\nExclusion Criteria:\n\n* Behavioural issues or poor instructability which might affect participation in the protocol\n* Significant visual disorders\n* Other diagnoses influencing gait\n* Not willing to sign informed consent before inclusion","ALL","4 Years","16 Years",{"count":20,"type":21},15,"ESTIMATED","OBSERVATIONAL","It is the clinical experience of the authors that some children with cerebral palsy who walk in crouch gait show sufficient knee extension during the clinical gait analysis, but walk in considerable knee flexion when they leave the gait laboratory. Possible differences between walking in a gait lab and walking in daily life may be caused by the effect of observational awareness in the lab (also known as the Hawthorne effect), and the lack of dual-tasks (DT) during the analysis (which are common during daily life walking). Since so far there is no technique to reliably measure gait kinematics in children with CP outside of the laboratory, the researchers aim to objectify the influence of both the Hawthorne effect and dual-tasks by introducing different conditions during a standard clinical 3D gait analysis.",[25,26,27,28,29],"Cerebral Palsy","Gait Disorders, Neurologic","Hawthorne Effect","Dual-tasks","Kinematics","RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2022-09-01",{"date":38,"type":21},"2028-12-01",{"name":40,"class":41},"Roessingh Research and Development","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":64,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100637471","balance-gait-and-motion-analysis-in-multiple-sclerosis-100637471","NCT07630311","\"Balance, Gait, and Motion Analysis in Multiple Sclerosis\"","\"Functional Assessment of Balance and Gait and Correlation With Kinetic and Kinematic Parameters in Patients With Multiple Sclerosis: Cross-Sectional Study\"","MS-BALGAIT","Inclusion Criteria:\n\n* Adults (≥ 18 years) with confirmed diagnosis of Multiple Sclerosis\n* Expanded Disability Status Scale (EDSS) score \\\u003C6\n* Ability to ambulate independently without the use of assistive devices\n* Absence of significant orthopedic or neurological conditions affecting mobility\n* Ability to understand and follow verbal instructions.\n\nExclusion Criteria:\n\n* History of injury or surgical intervention to the lower limbs or spine within the past year\n* Any musculoskeletal, neurological, cardiovascular, or other medical condition, other than Multiple Sclerosis, that may significantly affect gait or balance or compromise participant safety during testing.\n* Severe balance impairment or high risk of falling that prevents safe participation in single-leg stance, gait analysis, or obstacle negotiation tasks.","18 Years",{"count":53,"type":21},40,"The goal of this observational cross-sectional study is to investigate the relationship between functional measures of balance and gait and objective kinetic and kinematic parameters in people with Multiple Sclerosis (MS).\n\nThe main questions it aims to answer are:\n\ni) What is the relationship between kinetic and kinematic gait and balance parameters measured using the Vicon motion analysis system and performance on clinical functional assessments in people with Multiple Sclerosis?\n\nii) Which biomechanical parameters are most strongly associated with functional balance, gait, and physical performance outcomes?\n\nParticipants will attend a single laboratory-based assessment session. During this session, they will undergo biomechanical gait and balance analysis using the Vicon motion capture system, complete functional assessments of balance, gait, and physical performance, complete questionnaires assessing fear of falling and fatigue, and undergo assessment of lower-limb spasticity.",[56,26,57,58,59,60,29,61,62,63],"Multiple Sclerosis","Postural Balance","Motion Analysis","Biomechanics","Kinetics","Physiotherapy","Fatigue","Fall",[56,65,66,58,67,68,69,62,59],"Balance","Gait","Vicon System","Functional Assessments","Physical Performance","2026-06-21",{"date":72,"type":34},"2026-06-24",{"date":74,"type":34},"2025-09-01",{"date":76,"type":21},"2026-08-30",{"name":78,"class":41},"University of Patras",2,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":42},"100565659","usability-of-the-smart-hallway-system-in-clinical-setting-100565659","NCT06645054","Usability of the Smart Hallway System in Clinical Setting","Smart Hallway for Gait Assessment","SmartHallway","Inclusion Criteria:\n\n* ability to walk at least 10 metres without help of a person,\n* no severe cognitive problems (able to answer questionnaires),\n* native Slovenian speakers,\n* wiling to participate (signed informed consent)\n\nExclusion Criteria:\n\n* severe cognitive impairment,\n* not being able to walk with or without a prosthesis or orthosis.",{"count":89,"type":21},100,"The aim of the study is to examine suitability of data and processed reports acquired from the Smart Hallway system for clinical settings in terms of user acceptability and accuracy for use in clinical practice.",[92,26],"Amputation",[94,95,96,97,98],"Gait analysis","Computerised assessment","Rehabilitation","Lower limb loss","Prosthetics and orthotics","2026-06-11",{"date":101,"type":34},"2026-06-15",{"date":103,"type":34},"2024-03-24",{"date":105,"type":21},"2026-09",{"name":107,"class":41},"University Rehabilitation Institute, Republic of Slovenia",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":119,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":42},"100608078","percutaneous-ultrasound-guided-neuromodulation-to-improve-gait-rehabilitation-in-patients-who-have-suffered-a-stroke-100608078","NCT07196878","Percutaneous Ultrasound-guided Neuromodulation to Improve Gait Rehabilitation in Patients Who Have Suffered a Stroke.","Ultrasound-Guided Percutaneous Neuromodulation Protocol to Improve Gait Rehabilitation in Patients Who Have Suffered a Stroke. Clinical Trial.","Inclusion Criteria:\n\n1. Be between 18 and 70 years of age;\n2. Have suffered a stroke (CVA);\n3. Be in the subacute or chronic phase of the disease;\n4. Be able to walk 10 meters without assistance from another person;\n5. Currently be undergoing physiotherapy with conservative techniques;\n6. Be able to understand the technique being applied;\n7. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. Belonephobia (fear of needles);\n2. Allergy to needles or metals;\n3. Presence of uncontrolled coagulopathies;\n4. Presence of uncontrolled arterial disease;\n5. Pregnancy;\n6. Dermatological disorders;\n7. Presence of diseases such as systemic inflammatory disorders (e.g., rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or septic arthritis);\n8. Presence of diseases such as tumors, cancer, or metastases;\n9. Having received invasive physiotherapy treatment in the last 4 weeks.","70 Years",{"count":117,"type":21},30,"INTERVENTIONAL",[120],"NA","The goal of this clinical trial is to learn if percutaneous ultrasound-guided neuromodulation (NMP-e) can improve gait rehabilitation in adults who have suffered a stroke. The main questions it aims to answer are:\n\n* Does NMP-e improve walking speed in stroke survivors?\n* Does NMP-e enhance muscle strength, functional mobility, reduce spasticity, improve balance, and increase health-related quality of life?\n\nResearchers will compare the addition of NMP-e to conventional physiotherapy versus conventional physiotherapy alone to see if the intervention provides additional benefits in gait rehabilitation and other functional outcomes.\n\nParticipants will:\n\n* Continue their regular physiotherapy treatment consisting of passive and active-assisted mobilizations and strength exercises.\n* Receive NMP-e targeting the sciatic nerve at mid-thigh and the common peroneal nerve at the fibular head (experimental group only).\n* Undergo stimulation with an electrostimulator at 10 Hz for 10 seconds per trial, repeated 10 times, with intensity adjusted for comfort.\n* Be evaluated before the intervention, immediately after, and one week later using:\n* 10-Meter Walk Test for gait speed\n* Dynamometry for ankle plantarflexor and dorsiflexor strength\n* Time Up and Go test for functional mobility\n* Modified Modified Ashworth Scale for spasticity\n* Berg Balance Scale for balance\n* EuroQoL-5 Dimensions for health-related quality of life\n\nParticipants must be adults aged 18-70, able to walk 10 meters without assistance, currently receiving physiotherapy, and able to provide informed consent. Key exclusions include pregnancy, bleeding disorders, needle allergies, systemic inflammatory disorders, or recent invasive physiotherapy.\n\nThis randomized controlled trial will be conducted at ATECE, \\*\\*a Spanish association dedicated to the care and rehabilitation of individuals with acquired brain injury\\*\\*, where participants will be recruited and receive their interventions. The study aims to evaluate the potential of NMP-e as an adjunctive therapy for improving gait and related functional outcomes in subacute and chronic stroke patients.",[123,26],"Ictus",[125,126,127],"ICTUS","Gait disorder","Ultrasound guided neuromodulation","2026-06-10",{"date":130,"type":34},"2026-06-12",{"date":132,"type":34},"2025-09-15",{"date":134,"type":21},"2026-12-31",{"name":136,"class":41},"Alejandro Martín García",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":118,"phases":147,"briefSummary":148,"conditions":149,"keywords":160,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":192,"locationsCount":42},"100612195","development-and-efficacy-of-a-novel-cost-effective-gait-training-device-utilized-at-home-for-stroke-survivors-100612195","NCT07250425","Development and Efficacy of a Novel, Cost-Effective Gait Training Device Utilized at Home for Stroke Survivors","Development of a Novel, Cost-Effective Gait Training Device Utilized at Home for the Neurological Patient Population","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* First-ever ischemic or hemorrhagic stroke confirmed by medical record.\n* 3 months to 5 years post-stroke at time of enrollment.\n* Presence of lower-extremity motor impairment limiting walking function.\n* Able to stand for at least 30 minutes with no more than minimal assistance (with or without a device).\n* Medically stable and cleared by a physician to participate in moderate-intensity ambulation exercise.\n* Living in a home environment that can safely accommodate device installation (e.g., adequate space, appropriate flooring, and power access) as determined by the study team.\n* Able to understand study procedures and provide informed consent (or have a legally authorized representative), with sufficient cognitive and communication skills to follow simple instructions.\n* If assistance is required for transfers or device set-up, availability of a caregiver or assistant willing to participate in training and device use.\n\nExclusion Criteria:\n\n* Unstable cardiovascular, respiratory, or other medical conditions that contraindicate moderate- to high-intensity walking exercise (e.g., unstable angina, decompensated heart failure, uncontrolled arrhythmias).\n* Severe musculoskeletal or orthopedic conditions limiting safe participation in supported stepping (e.g., unstable fractures, severe contractures preventing positioning in the device).\n* Severe spasticity or movement disorders that would preclude safe use of the device, based on investigator judgment.\n* Severe cognitive impairment, aphasia, or behavioral disturbance that would prevent informed consent or safe participation.\n* Progressive neurological conditions (e.g., progressive neurodegenerative disease) expected to significantly worsen over the 12-week study period.\n* Current participation in another interventional trial targeting gait or lower-extremity function.\n* Any other condition that, in the opinion of the investigators, would make participation unsafe or interfere with study adherence or outcome interpretation.","75 Years",{"count":146,"type":21},20,[120],"This pilot, parallel-group randomized controlled trial will evaluate the feasibility, safety, usability, and preliminary efficacy of the Rise\\&Walk InHome (RWH), a novel robotic gait training device designed for home use after stroke. Twenty adults with lower-extremity motor impairment following a first-ever stroke (3 months to 5 years post-event) will be randomized 1:1 to either (1) RWH-assisted home walking plus usual care or (2) usual care alone for 12 weeks. Participants in the intervention group will receive an in-home RWH device, complete a structured device training program, and be instructed to perform 30-minute RWH walking sessions four times per week (48 sessions total). All participants will undergo standardized outcome assessments at baseline, weeks 4, 8, and 12, including the 6-Minute Walk Test (primary outcome), 10-Meter Walk Test, daily step count via wearable activity tracker, and health-related quality of life (SF-36). Additional feasibility and usability outcomes include device use and adherence, patient satisfaction and motivation, ease of use, perceived exertion, and adverse events. Findings will inform the feasibility of in-home deployment of the RWH device and provide preliminary effect-size estimates to guide the design of a larger efficacy trial.",[150,151,152,26,153,154,155,156,157,158,159],"Stroke","Neurological Diseases or Conditions","Hemiparesis;Poststroke\u002FCVA","Post Stroke Fatigue","Motor Recovery","Walking Difficulty","Balance Impairment","Falls Prevention","Hemiparesis","Mobility Limitation",[161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184],"in-home rehabilitation","Robotic-Assisted Gait Training","gait training device","stroke recovery","functional mobility","rehabilitation technology","remote monitoring","rehabilitation robotics","Fitbit Step Tracking","Self-Directed Gait Training","high-intensity gait training","Neurorehabilitation Research","Lower Limb Rehabilitation","Motor Function Recovery","Physical Therapy","Walking Endurance","task specific walking practice","neurological recovery","stroke rehabilitation","home exercise program","Rise&Walk InHome","daily step count","6-minute walk test","10-meter walk test","NOT_YET_RECRUITING","2026-03-06",{"date":188,"type":34},"2026-03-09",{"date":190,"type":21},"2026-08",{"date":190,"type":21},{"name":193,"class":41},"Healing Innovations",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":115,"enrollmentInfo":201,"targetDuration":4,"studyType":118,"phases":202,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":42},"100628409","safety-and-feasibility-of-twiice-rise---phase-2-100628409","NCT07461259","Safety and Feasibility of TWIICE Rise - Phase 2","Two-phase Pilot Study on the Safety and Feasibility of TWIICE Rise for Exoskeleton-assisted Ambulation in Patients With Spinal Cord Injury","Inclusion Criteria:\n\n1. Informed Consent signed by the subject.\n2. Traumatic and non-traumatic SCI\n3. Motor incomplete SCI with Neurological Level of Injury (NLI) C5-L5, or Motor Complete SCI with NLI T1-L5 as determined by the ISNCSCI.\n4. Male and non-pregnant, non-lactating female aged 18 to 70 years old\n5. At least 6 months after injury\n6. Able to stand or maintain upright position with a standing device (e.g., 'Easy stand') for at least ten minutes without clinical symptoms of orthostatic hypotension.\n7. Able to use crutches.\n8. Able to sit with knees and hips \\>= 90° flexion\n9. Phase 1: Height of 160 to 180 cm, Phase 2: Height of 160 to 190 cm\n10. Phase 1: Weight of \\\u003C80 kg, Phase 2: Weight of \\\u003C100 kg\n\nExclusion Criteria:\n\n1. History of severe neurological injuries other than spinal cord injury (e.g., Multiple Sclerosis, Cerebral Palsy, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury, Stroke)\n2. Ability to walk 10 meters without physical assistance of a person\n3. Severe concurrent medical disease, illness, or condition\n4. Systemic or peripheral infection influencing wearing an exoskeleton.\n5. Diagnosis of coronary artery disease that precludes moderate to intense exercise.\n6. A medical diagnosis in the patient chart of atherosclerosis, congestive heart failure, or history of myocardial infarction\n7. Individuals with a pacemaker, defibrillator, drug delivery pump, or other electrical devices if malfunctions could lead to serious adverse events.\n8. Deep vein thromboses in lower extremities of less than 6 months duration.\n9. Untreated sever hypertension (systolic blood pressure \\>180 mmHg, diastolic blood pressure \\>120 mmHg)\n10. Unstable spine or unhealed limbs\n11. History of lower extremities or pelvic fragility fractures within the last two years\n12. Heterotopic ossification that impairs joint mobility\n13. Significant contractures defined as flexion contracture limited to 20 the hip and knee.\n14. Severe spasticity (Modified Ashworth grade 4) or uncontrolled clonus\n15. Diagnosis of severe osteoporosis\u002Fpenia: Dual Energy X-ray Absorptiometry (DXA) results indicating a t-score below -3.5 at the femoral neck or the total proximal femur bone, and knee bone mineral density (BMD) \\\u003C 0.60 gm\u002Fcm2\n16. Current pressure ulcer of the arms, trunk, pelvic area, or lower extremities\n17. Psychiatric or cognitive conditions that may interfere with the trial.\n18. Pregnancy or women who plan to become pregnant during the study period, and lactating women.\n19. Patient is currently involved in any other interventional study.\n20. Other severe illness that the study physician considers in his\u002Fher clinical judgment to be exclusionary.",{"count":20,"type":21},[120],"The aim of this study is to assess the safety and the feasibility of two versions of TWIICE Rise for exoskeleton-assisted ambulation in patients with a spinal cord injury.\n\nThis study is done in two phases:\n\nThe first phase evaluates the safety and feasibility of TWIICE Rise 0.0 with 5 patients over 6 sessions in clinic. The second phase is being conducted with TWIICE Rise 1.0. This version has potentially improved functionalities based on feedback from Phase 1. Safety and feasibility will be assessed with 10 patients over 10 sessions in different settings (clinic, home, and community environment).",[205,26],"Spinal Cord Injuries",[207,208,209,210,211,212,213,214,215,216,217,218,219],"Spinal Cord Injury","Exoskeleton","Robotics","Gait Rehabilitation","Lower-limb","Neurorehabilitation","Paraplegia","Walking","Assistive technology","Usability","Feasibility","Home use","Community use","2026-03-04",{"date":222,"type":34},"2026-03-10",{"date":224,"type":34},"2023-07-25",{"date":226,"type":21},"2027-07-31",{"name":228,"class":229},"TWIICE","INDUSTRY",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":240,"conditions":241,"keywords":244,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":42},"100602032","ultrasonographic-assessment-of-muscle-morphology-function-and-clinical-findings-in-spastic-cerebral-palsy-100602032","NCT07118228","Ultrasonographic Assessment of Muscle Morphology, Function, and Clinical Findings in Spastic Cerebral Palsy","Evaluation of the Relationship Between Ultrasonographic Muscle Morphology, Functional Properties, and Clinical Parameters in Children With Spastic Cerebral Palsy","US-sCP","Inclusion Criteria:\n\n* Diagnosis of spastic cerebral palsy (SCP) according to the criteria defined by Rosenbaum et al. (2007)\n* Age between 4 and 18 years\n* Gross Motor Function Classification System (GMFCS) Level I, II, or III\n* Manual Ability Classification System (MACS) Level I, II, III, or IV\n\nExclusion Criteria:\n\n* Non-spastic types of cerebral palsy (e.g., dyskinetic, ataxic)\n* Diagnosis of neuromuscular disorders other than cerebral palsy (e.g., hereditary neuropathy, myopathy)\n* Presence of muscle contractures or fixed deformities in the limbs selected for ultrasound and clinical assessment\n* Cognitive or behavioral impairments that prevent cooperation during ultrasound or clinical evaluation\n* Botulinum toxin-A (BoNT-A) injection applied to the target muscles within the last 6 months\n* Current treatment with oral or intrathecal antispastic medications\n* History of orthopedic surgery or selective dorsal rhizotomy involving the target muscles\n* Acute infection, febrile illness, or severe systemic disease (e.g., advanced heart failure, respiratory insufficiency) that may compromise the safety of assessments",{"count":239,"type":21},36,"This study focuses on children with spastic cerebral palsy and aims to examine how muscle morphology and tissue characteristics, as assessed by ultrasound, may relate to functional motor abilities. It is designed as a prospective, cross-sectional, observational study. Planned ultrasound-based assessments include parameters such as muscle thickness, pennation angle, fascicle length, echo intensity, tissue stiffness (via shear wave elastography), and microvascular flow (via superb microvascular imaging). These measurements are intended to be compared with standard clinical evaluations, including the GMFCS, GMFM-66, MAS, MACS, and Tardieu Scale. The study seeks to contribute to a better understanding of the relationship between muscle architecture and functional outcomes, with the goal of generating insights that may inform individualized rehabilitation planning.",[242,26,243],"Muscle Spasticity","Cerebral Palsy, Spastic",[245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260],"Spastic Cerebral Palsy","Muscle Morphology","Shear Wave Elastography","Muscle Architecture","Superb Microvascular Imaging","Muscle Stiffness","Pennation Angle","Fascicle Length","Intramuscular Vascularity","Echo Intensity","GMFM-66","Gross Motor Function","Muscle Morphology and Function","Ultrasound Imaging","Ultrasound Imaging of Spastic Muscle","Functional Assessment","2026-01-30",{"date":263,"type":34},"2026-02-03",{"date":265,"type":34},"2025-12-15",{"date":267,"type":21},"2026-06-30",{"name":269,"class":41},"Kocaeli University",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":16,"minAge":278,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":118,"phases":281,"briefSummary":282,"conditions":283,"keywords":286,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":42},"100608084","effect-of-electromagnetic-field-therapy-on-balance-and-gait-in-paraparetic-patients-100608084","NCT07196956","Effect of Electromagnetic Field Therapy on Balance and Gait in Paraparetic Patients","The Role of Electromagnetic Field Therapy in Improving Perturbation of Balance and Gait Disorders in Paraparetic Patients","EMT-BG","Inclusion Criteria:\n\n* Diagnosis of paraparesis with spinal cord lesion level between T6 and T12. Age between 25 and 45 years. Muscle spasticity graded as II or III on the Modified Ashworth Scale (MAS) for hip adductors and ankle plantar flexors.\n\nMedically and psychologically stable. Conscious and cooperative, able to follow instructions. Able to provide informed consent.\n\nExclusion Criteria:\n\n* Presence of metal implants or pacemakers (contraindicated for electromagnetic therapy).\n\nHistory of seizures or epilepsy. Active malignancy or infection. Severe cognitive or psychiatric impairment that would interfere with participation.\n\nUse of alcohol or recreational drugs during the study period. Participation in another concurrent physical or electromagnetic therapy trial. Unstable medical condition (e.g., uncontrolled hypertension, cardiovascular disease).","15 Years","45 Years",{"count":117,"type":21},[120],"This study will investigate whether adding electromagnetic field therapy (EMT) to a standard physical therapy program is more effective than physical therapy alone for improving balance and walking ability in paraparetic patients.\n\nThirty patients with paraparesis (weakness in the lower limbs) due to spinal cord lesions between levels T6 and T12 will be randomly assigned to one of two groups. Both groups will receive a 45-minute physical therapy session, three times per week for two months. The physical therapy program will include stretching, strengthening, balance, and gait training exercises.\n\nThe key difference will be that one group (Group II) will also receive active low-frequency (0.5 Hz) electromagnetic therapy applied to their spine during their sessions, while the other group (Group I) will receive a placebo (inactive) EMT device.\n\nPatients will be assessed before and after the 2-month treatment period. The assessments will measure muscle spasticity (using the Modified Ashworth Scale), balance (using the Biodex Balance System), and detailed gait parameters like step length, stride length, and base of support (using a 3D motion analysis system",[284,26,285],"Paraparesis","Postural Balance Disorders",[287,288,289,290,96,291,58,292],"Electromagnetic Field Therapy","Electromagnetic Stimulation","Physical Therapy Modalities","Spasticity","Biodex Balance System","Modified Ashworth Scale","2026-01-01",{"date":295,"type":34},"2026-01-05",{"date":297,"type":21},"2026-01-11",{"date":299,"type":21},"2026-03-01",{"name":301,"class":41},"MTI University",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":118,"phases":312,"briefSummary":313,"conditions":314,"keywords":315,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":42},"100453677","effectiveness-of-a-powered-exoskeleton-combined-with-fes-for-patients-with-chronic-sci-a-rct-100453677","NCT05187650","Effectiveness of a Powered Exoskeleton Combined With FES for Patients With Chronic SCI: a RCT","Effectiveness of a Powered Exoskeleton Combined With Functional Electric Stimulation for Patients With Chronic Spinal Cord Injury: a Randomized Controlled Trial","Ekso-FES","Inclusion Criteria:\n\n* chronic, incomplete SCI (\\> 1 year, AIS B-D)\n* traumatic or non-traumatic lesion\n* capacity to stand up and perform a 10MWT with or without medical aids\n* partially wheelchair dependent\n* intact lower motoneuron on the segmental innervation level of M. glutaeus maximus, Mm. ischiocrurales, M. tibialis anterior and M. quadriceps (to guarantee the stimulability with FES)\n\nExclusion Criteria:\n\n* Exoskeleton device related contraindications: \\> 100 kg body weight; Body height: \\\u003C 155 cm or \\> 190 cm; pelvic width: \\> 46 cm\n* orthopedic limitations (acute fractures of the lower limb)\n* contractures\n* heterotrophic ossification\n* spasticity (modified Ashworth Scale \\>3)\n* skin injuries of the lower limbs in areas where the skin has contact with the exoskeleton\n* Unstable circulation (unable to stand for at least 10 minutes)\n* acute deep vein thrombosis\n* pregnancy (tested in women of childbearing age (15 - 49 years))",{"count":311,"type":21},34,[120],"While there are a number of prospective studies evaluating powered exoskeletons in SCI patients, to date, not a single well-designed, randomized clinical trial has been published. However, there is evidence for beneficial effects of over-ground exoskeleton therapy on walking function post-intervention from a meta-analysis on non-randomized, uncontrolled studies. Functional electrical stimulation (FES), on the other hand, is a common and established method for the rehabilitation of persons with SCI and has been demonstrated to be beneficial in, e.g., improving muscle force, power output and endurance.\n\nCombining FES and overground robotic therapy within the same therapy session could potentially merge and potentiate the effects of each separate treatment, making it a very powerful and efficient therapy method. Up to date, however, comparative studies evaluating benefits of this combined approach (i.e., powered exoskeleton and FES) to robotic therapy without FES are missing.",[205,26],[316,317,208,318,319],"SCI","Functional Electrical Stimulation","Robotic device","Robotic overground gait training","2025-12-10",{"date":322,"type":34},"2025-12-18",{"date":324,"type":34},"2022-03-18",{"date":326,"type":21},"2027-12-31",{"name":328,"class":329},"Mario Widmer","NETWORK",{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":144,"enrollmentInfo":337,"targetDuration":4,"studyType":118,"phases":339,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":42},"100615175","development-of-a-novel-strategy-to-analyze-the-effect-on-gait-using-transcutaneous-spinal-current-stimulation-in-incomplete-spinal-cord-injured-patients-100615175","NCT07289191","Development of a Novel Strategy to Analyze the Effect on Gait Using Transcutaneous Spinal Current Stimulation in Incomplete Spinal Cord Injured Patients","Design of tSCS Strategies to Promote Neural Plasticity and Improve Functional Outcomes During Rehabilitation of Locomotion","Inclusion Criteria:\n\n* Male or female more than 18 years old;\n* With a stable traumatic o nor traumatic incomplete motor cervical or thoracic SCI;\n* Time since SCI more than 6 months;\n* American Spinal Injury Association Impairment Scale (AIS)-D who could realize gait at least 6 meters with or without technical help;\n* Capacity for compression the nature of the study and signed informed consent.\n\nExclusion Criteria:\n\n* Unstable medical condition (cancer, acute infections, etc.);\n* Severe spasticity (≥ 3 score on the Modified Ashworth scale (MAS)),\n* Peripheral nerve affectation;\n* Ulcers on the electrode applied area;\n* Intolerance of tSCS.",{"count":338,"type":21},10,[120],"To determine whether the combination of non-invasive spinal cord stimulation together with gait rehabilitation reduces spasticity and facilitates recovery of lower limb motor strength and gait function in patients with incomplete SCI, as well as studying the underlying physiopathological changes following incomplete SCI and its modulation by non-invasive stimulation techniques.",[205,342,26,343,344],"Non Invasive Spinal Stimulation","Motor Function; Retardation","Stimulation Charecteristic","2025-12-04",{"date":347,"type":34},"2025-12-17",{"date":349,"type":34},"2021-01-01",{"date":351,"type":21},"2026-02-01",{"name":353,"class":41},"Institut Guttmann",{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":144,"enrollmentInfo":360,"targetDuration":4,"studyType":118,"phases":361,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":42},"100428191","investigating-the-effects-of-wearable-robotic-exoskeleton-for-improving-mobility-and-cognition-in-persons-with-ms-100428191","NCT04855825","Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS","Inclusion Criteria:\n\n* Be diagnosed with multiple sclerosis.\n* Be determined by the study staff to have moderate to severe difficulty walking but still be able to walk while using the robotic exoskeleton.\n* Have some difficulty thinking and problem solving as determined by my performance on a special test that I will take during the screening visit.\n* Be between the ages of 18 and 75.\n* Be free from flair ups of my MS Symptoms for at least one month prior to testing.\n* Discuss with study staff how to maintain a constant level of my spasticity medication (for example baclofen) throughout the study.\n* Be able to walk (with the use of one or more assistive device if needed).\n* Have English as my primary language.\n* Be able to physically fit into the exoskeleton device: height between 60 and 76\", weight under 220 lbs.\n* Be able to tolerate upright standing for 30 minutes with assistance if needed.\n* Have normal joint range of motion for walking as determined by study staff.\n* Have sufficient strength to use the hemiwalker, bilateral canes or walker while wearing the RE.\n* Have stable blood pressure.\n* Be willing and able to give informed consent.\n* Be able and willing to comply with study procedures and follow directions and commands, verbal instructions, and follow-up requirements.\n\nExclusion Criteria:\n\n* Have a history of head injury, stroke, seizures, or any other significant neurological history other than MS.\n* Have a high degree of difficulty in thinking and problem solving that prevents me from participating in the study as determined by my performance on a special test taken during the screening visit.\n* Be currently taking steroids, benzodiazepines, antipsychotics, and\u002For neuroleptics as determined by study staff review of my medications.\n* Be pregnant.\n* Be completely reliant on a wheelchair.\n* Have joint contracture or spasticity of any limb that limits normal range of motion during walking with assistive devices as determined by study staff.\n* Have skin issues that would prevent wearing the RE.\n* Have pressure sore stage 2 or higher located in an area that would negatively affect weight bearing, harness fit, or therapist assistance.\n* Have orthopedic issues or history that will interfere with walking or limit the range of motion of the lower limbs (e.g., knee replacement, inflammation)\n* Have been hospitalized for heart attack, heart surgery or acute heart failure within 3 months of enrollment in study.\n* Have any other medical conditions that my doctor or physical therapist feels would affect my ability to use the robotic device.\n* Have a pacemaker or other implanted electrical device, brain stimulator, aneurysm clip (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and internal hearing aids \\[cochlear implants\\]), permanent eyeliner, implanted delivery pumps, or shrapnel fragments.\n* Have dental implants- I should discuss any dental implants with the investigators.\n* Have been told by my doctor that it is unsafe for me to have a regular MRI as part of my medical care.",{"count":338,"type":21},[120],"The purpose of this research study is to evaluate the usefulness of a wearable robotic exoskeleton device (Ekso-GT), to improve learning and memory, and gait therapy in persons with walking disability due to Multiple Sclerosis. The study will evaluate the mobility, learning and memory, and walking abilities of individuals with multiple sclerosis who went through the traditional as compared to others who used the robotic exoskeleton as part of their therapy.",[56,26,364,365],"Motility Disorder","Cognitive Impairment","2025-11-19",{"date":368,"type":34},"2025-11-24",{"date":370,"type":34},"2017-10-05",{"date":372,"type":21},"2027-12-30",{"name":374,"class":41},"Kessler Foundation",{"id":376,"slug":377,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":16,"minAge":382,"maxAge":51,"enrollmentInfo":383,"targetDuration":4,"studyType":118,"phases":385,"briefSummary":386,"conditions":387,"keywords":388,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":42},"100426753","serious-game-based-intervention-in-gait-rehabilitation-for-children-with-cerebral-palsy-100426753","NCT04837105","Serious Game-based Intervention in Gait Rehabilitation for Children With Cerebral Palsy","Serious Game-based Intervention in Gait Rehabilitation for Children With Cerebral Palsy: Randomized Control Trial","Inclusion Criteria:\n\n* A clinical diagnosis of CP mentioned in the medical record\n* Minor child for the entire duration of the protocol, i.e. between 10 and 17 years of age (the child must be less than 18 years of age at the time of the last check-up scheduled 1 year after inclusion in the study)\n* Global Motor Function Classification System (GMFCS) levels I to III\n* Functional Mobility Scale 50 meters rating superior or equal to 2 (ability to walk on 50m using a walker or frame without help from another person)\n* Ability to cooperate, understand and follow simple instructions to play.\n* Patient affiliated to the French social security system\n* Voluntary patient whose parents have given their consent for their child to participate in the study\n* Patient who has undergone multisite surgery of the lower limbs including bone procedures at least 7 weeks before the start of the procedure\n\nExclusion Criteria:\n\n* A diagnosis of photosensitive epilepsy mentioned in the medical file AND\u002FOR a mention in the child's medical file or by the parents or by the child of a history of epileptic seizures occurring during the practice of a video game\n* A visual, cognitive or auditory impairment at a level that would interfere with playing the game. The patient must have normal or corrected vision and hearing.","10 Years",{"count":384,"type":21},14,[120],"Cerebral palsy (CP) is defined as a group of movement and posture disorders that cause activity limitation due to brain damage during fetal development or in the first year of life. Motor activities, and in particular walking, can be affected by many factors including sensory deficits, biomechanical and postural limitations, muscle weakness and spasticity. Theories of gait training guide rehabilitation management strategies. Among these, intensification, variability and specific training of walking parameters (speed, step length, cadence) have shown their effectiveness. Delivering sensory feedback during gait rehabilitation exercises is a complementary approach to improve motor learning during rehabilitation. On the other hand, motivation is a key factor in the success of rehabilitation. The addition of walking exercises performed through a serious game in augmented reality (AR) appears relevant for the rehabilitation of children with CP after surgery.\n\nThe serious game ARRoW-CP is based on the latest advances in the literature in terms of gait rehabilitation protocol but also on the results of a clinical study conducted by our team, to identify the best feedback modalities to be delivered during the serious rehabilitation game.",[25,26],[389,390,391,392],"physiotherapy","gait rehabilitation","serious game","multi level surgery","2025-08-19",{"date":395,"type":34},"2025-08-24",{"date":397,"type":34},"2021-04-15",{"date":399,"type":21},"2025-12-31",{"name":401,"class":41},"Fondation Ellen Poidatz",{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":144,"enrollmentInfo":409,"targetDuration":4,"studyType":118,"phases":410,"briefSummary":412,"conditions":413,"keywords":416,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":431},"100598576","phase-2-efficacy-of-cerebello-spinal-direct-current-stimulation-csdcs-on-functional-mobility-in-chronic-stroke-patients-100598576","NCT07073287","Efficacy of Cerebello-spinal Direct Current Stimulation (csDCS) on Functional Mobility in Chronic Stroke Patients","Efficacy of Cerebello-spinal Direct Current Stimulation on Functional Mobility in Chronic Stroke Patients","Inclusion Criteria:\n\n* Confirmation of Stroke by digital or physical imaging or medical report\n* Gait impairment\n* Stroke with at least 6 months after ictus\n\nExclusion Criteria:\n\n* Metallic implants in spinal cord\n* Major orthopedic\u002Frheumatological disorders\n* Inability of verbal or non-verbal communication",{"count":117,"type":21},[411],"PHASE2","The aim of this clinical trial is to determine if cerebello-spinal direct current stimulation (csDCS) is effective in treating gait disorders in individuals with chronic stroke. Additionally, the trial seeks to evaluate the safety of this technique.\n\nThe primary objectives include:\n\nInvestigating whether cerebello-spinal direct current stimulation improves gait and functional mobility in participants with chronic stroke.\n\nAssessing any potential side effects associated with the method.\n\nResearchers will conduct a comparative analysis between cerebello-spinal direct current stimulation and a sham procedure (which mimics the stimulation without any actual effect) to assess its effectiveness in addressing gait disorders and enhancing mobility.\n\nParticipants in the trial will:\n\nUndergo cerebello-spinal direct current stimulation combined with treadmill training or a sham procedure with treadmill training daily over a two-week period.",[414,26,415],"Stroke Rehabilitation","tDCS",[417,418,419,420,421],"spinal cord","stroke","gait","rehabilitation","direct current stimulation","2025-07-09",{"date":424,"type":34},"2025-07-18",{"date":426,"type":34},"2024-05-01",{"date":428,"type":21},"2026-08-01",{"name":430,"class":41},"Universidade Federal de Pernambuco",3,{"id":433,"slug":434,"hasResults":11,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":439,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":451,"locationsCount":42},"100585738","brain-activity-during-complex-walking-in-people-with-atypical-parkinsonian-syndromes-100585738","NCT06906276","Brain Activity During Complex Walking in People With Atypical Parkinsonian Syndromes","Walking and Thinking - Brain Activity During Complex Walking in Atypical Parkinsonian Syndromes","Inclusion Criteria:\n\n* clinical diagnosis of PSP according to Movement Disorder Society (MDS) (2017) or\n* MSA according to MDS criteria (2022)\n* the ability to walk with or without a mobility device for ≤5 minutes continuously\n\nExclusion Criteria:\n\n* cognitive difficulties affecting the ability to understand and\u002For follow verbal\u002Fwritten - instructions\n* severe freezing of gait\n* Severe hearing or visual impairments that affect participation in the assessments\n* Other neurological diseases\n* Other diseases that can affect gait or balance.",{"count":117,"type":21},"Every-day life means being part of a complex environment and performing complex tasks that usually involve a combination of motor and cognitive skills. However, the process of aging or the sequelae of neurological diseases such as atypical Parkinson's disease (APD) compromises motor-cognitive interaction necessary for an independent lifestyle. While motor-cognitive performance has been identified as an important goal for sustained health across different clinical populations, little is known about underlying brain function leading to these difficulties and how to best target these motor-cognitive difficulties in the context of rehabilitation and exercise interventions.\n\nThe challenge of improving treatments of motor-cognitive difficulties (such as dual-tasking and navigation) is daunting, and an important step is arriving at a method that accurately portrays these impairments in an ecologically valid state. The investigators aim therefore to explore brain function during complex walking in healthy and APD by investigating the effects of age and neurological disease on motor-cognitive performance and its neural correlates during three conditions of complex walking (dual-task walking, navigation and a combination of both) using non-invasive measures of brain activity (functional near infrared spectrometry, fNIRS) and advanced gait analysis in real time in older healthy adults and people with APD.",[26,442,443,444],"Atypical Parkinson Disease","fNIRS","Aging","2025-07-04",{"date":447,"type":34},"2025-07-08",{"date":449,"type":34},"2025-03-14",{"date":326,"type":21},{"name":452,"class":41},"Karolinska Institutet",{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":144,"enrollmentInfo":459,"targetDuration":4,"studyType":118,"phases":460,"briefSummary":461,"conditions":462,"keywords":464,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":431},"100561670","efficacy-of-trans-spinal-magnetic-stimulation-on-functional-mobility-in-chronic-stroke-patients-100561670","NCT06593184","Efficacy of Trans-spinal Magnetic Stimulation on Functional Mobility in Chronic Stroke Patients","Inclusion Criteria:\n\n* Confirmation of Stroke by digital or physical imaging or medical report\n* Gait impairment\n* Stroke with at least 6 months after ictus\n\nExclusion Criteria:\n\n* Metallic implants in spinal cord\n* Major orthopedic\u002Frheumatological disorders\n* Incapacity of verbal or non-verbal communication",{"count":117,"type":21},[120],"The goal of this clinical trial is to learn if trans-spinal magnetic stimulation works to treat gait disorders in chronic stroke adults. It will also learn about the safety of trans-spinal magnetic stimulation.\n\nThe main questions it aims to answer are:\n\nDoes trans-spinal magnetic stimulation enhance chronic stroke participants gait and functional mobility? Does the technique cause any side effects?\n\nResearchers will compare trans-spinal magnetic stimulation to a sham (a look-alike stimulation with no real effect) to see if trans-spinal magnetic stimulation works to treat gait disorders and improve functional mobility.\n\nParticipants will:\n\nReceive trans-spinal magnetic stimulation with treadmill training or a sham stimulation with treadmill training every day for 2 weeks.",[463,26,150],"Stroke Sequelae",[465,466,467,150],"Spinal cord","Magnetic Stimulation","Trans-spinal magnetic stimulation","2025-06-18",{"date":470,"type":34},"2025-06-24",{"date":472,"type":34},"2024-06-01",{"date":474,"type":21},"2025-08-01",{"name":430,"class":41},{"id":477,"slug":478,"hasResults":11,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":118,"phases":485,"briefSummary":486,"conditions":487,"keywords":490,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":42},"100592538","correlation-of-stn-dbs-induced-visuospatial-changes-and-freezing-of-gait-100592538","NCT06994728","Correlation of STN-DBS Induced Visuospatial Changes and Freezing of Gait","Characterization of Subthalamic Nucleus Deep Brain Stimulation Laterality on Visuospatial Attention and Correlation to Freezing of Gait in Parkinson's Disease","Inclusion Criteria:\n\n* Subjects above 18 years of age\n* Subjects with freezing of gait\n* Subjects with bilateral STN-DBS surgery as part of their clinical care for Parkinson's disease\n\nExclusion Criteria:\n\n* Uncorrected visual or hearing impairments, as indicated by self-report\n* Individuals who are pregnant or expect to become pregnant during the course of the study\n* Individuals with dementia or relevant brain lesions impacting cognition or gait",{"count":484,"type":21},12,[120],"The purpose of this research is to determine how deep brain stimulation (DBS) for Parkinson's disease affects attention and visuospatial function. Additionally, this study will evaluate how deficits in visual attention are associated with freezing of gait (FOG) in Parkinson's disease. There is currently no reliable treatment for FOG and little is understood about the underlying reason this occurs. Some recent research has found that stimulating the right side of the brain seems to improve FOG. The right side of the brain is also paramount for visual attention, which is why investigators are conducting this study.",[488,26,489],"Parkinson Disease","Visuospatial\u002FPerceptual Abilities",[491,492,493,494],"Freezing of gait","Subthalamic nucleus","Visuospatial attention","Deep brain stimulation","2025-05-20",{"date":497,"type":34},"2025-05-29",{"date":499,"type":34},"2025-04-01",{"date":501,"type":21},"2026-06",{"name":503,"class":41},"Medical University of South Carolina",{"id":505,"slug":506,"hasResults":11,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":11,"sex":511,"minAge":51,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":118,"phases":514,"briefSummary":515,"conditions":516,"keywords":534,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":571,"locationsCount":79},"100397880","phase-2-locomotor-training-with-testosterone-to-promote-bone-and-muscle-health-after-spinal-cord-injury-100397880","NCT04460872","Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury","Locomotor Training With Testosterone to Promote Bone and Muscle Health","Inclusion Criteria:\n\n* Men \\>18 years of age\n* Diagnosis of an incomplete SCI involving spinal segments L1 or above or a clinically complete SCI involving spinal segments T2-L1, with upper motor neuron injury signs (i.e., spasticity, hypertonicity) for \\>60-days\n* Low serum total testosterone (\\\u003C300 ng\u002FdL), bioavailable testosterone (\\\u003C110 ng\u002FdL), or free testosterone (\\\u003C46 pg\u002FmL or \\\u003C4.6 ng\u002FdL)\n* Presence of one or more sign or symptom that may be related to low testosterone, including: loss of body hair or reduced shaving, very small testes (\\\u003C6 mL), reduced sexual desire (libido) and activity, decreased spontaneous erections (e.g., morning erections) or erectile dysfunction, breast discomfort or gynecomastia, height loss, low-trauma fracture, or low BMD, hot flushes or sweats, decreased energy, motivation, initiative, or self-confidence, fatigue or irritability, feeling sad or blue, having a depressed mood, or having a persistent low-grade depressive disorder, poor concentration or memory, sleep disturbances or increased sleepiness, mild unexplained anemia (normochromic or normocytic), reduced muscle bulk, strength, or physical performance, Increased body fat or body mass index, any other sign or symptom commonly associated with low testosterone\n* Locomotor dysfunction, definted as self-selected walking pace ≤1.0 m\u002Fs on a 10mWT, either with or without gait devices or braces and with or without assistance, or as self-selected walking pace \\>1.0 m\u002Fs with reliance on a gait device or brace or with highly compensated movement impairments, as identified by a trained observer.\n* Diagnosis of first time SCI including etiology from trauma, vascular, or orthopedic pathology\n* Medically-stable condition that is asymptomatic for conditions that will interfere with the study participation\n* Willingness to administer TRT as instructed by the study staff and to abide by study protocol\n* Documented approval from the study physician verifying medical status\n\nExclusion Criteria:\n\n* Currently participating in another research protocol that may influence study outcomes.\n* Mental state that precludes understanding the study protocol.\n* Life expectancy \\\u003C12-months.\n* History of or current congenital SCI (e.g., Chiari malformation, myelomeningocele, intraspinal neoplasm, Frederich's ataxis) or other degenerative spinal disorder (e.g., spinocerebellar degeneration) that may complicate study procedures\n* Multiple sclerosis, amyotrophic lateral sclerosis, or other neurologic impairment or injury\n* Current prostate, breast, or other organ cancer or a history of prostate or breast cancer\n* Any other diagnosed or treated cancer within the past 24-months, with the exceptions of basal or squamous cell carcinoma of the skin that has been successfully treated\n* Serum prostate-specific antigen (PSA) \\>3.0 ng\u002FmL \\[men treated with 5-alpha reductase inhibitors (e.g., finasteride or dutasteride) are eligible to participate if PSA values are ≤1.5 ng\u002FmL\\]\n* Prostate nodule or induration noted on digital rectal exam (DRE) during screening that tests positive for prostate cancer\n* Currently seeking fertility or expected during the duration of the study\n* Gynecomastia\n* Hematocrit (HCT) \\>49%\n* Any major cardiovascular (CV) event within the last 12-months (defined as a history of acute myocardial infarction, any cardiac revascularization procedure including angioplasty, stenting, or coronary artery bypass grafting, revascularization of the carotid or middle cerebral artery or procedures to treat critical limb ischemia, or hospitalization due to unstable angina, transient ischemic attack, stroke, or peripheral vascular disease)\n* Angina that is not controlled on a current medical regimen (Canadian class II, III, or IV)\n* Poorly compensated congestive heart failure (NYHA class III or IV)\n* Poorly controlled hypertension (consistently measured systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg), while on medications\n* Poorly controlled arrhythmia of any type\n* Severe valvular heart disease\n* Baseline electrocardiogram (ECG) findings such as left bundle branch block or marked ECG abnormalities that would preclude serial screening evaluations for occult ischemic events\n* History of unprovoked deep venous thrombosis (DVT), unprovoked pulmonary embolism, history of recurrent DVT or known thrombophilia\n* LDL cholesterol \\>160 mg\u002FdL with history of any major CV event, defined above, within the last 12-months\n* Major non-CV surgery (e.g., major abdominal or thoracic procedure) within 90-days prior to screening and\u002For a major surgery scheduled at the time of screening\n* Liver enzymes (AST or ALT) \\>1.5 times the normal upper limit\n* Severe or end-stage chronic kidney disease documented by estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\n* Diagnosed, but untreated severe obstructive sleep apnea\n* Lower extremity fracture in the last 12-months (exclusion criterion for participation in LT+TRT group only)\n* Femoral neck, total hip, or lumbar spine t-score below -2.5 or distal femur BMD \\\u003C0.70 g\u002Fcm2, assessed via DEXA at screening (exclusion criterion for participation in LT+TRT group only)\n* Current anticoagulant therapy (contraindication for i.m. injections)\n* Use of any of the following pharmacologic agents in the previous 90-days: any TRT formulation, any compounded or over-the-counter androgenic hormones or androgen precursors, clomiphene, aromatase inhibitors, anti-estrogen or estrogen treatment, or growth hormone\n* Use of anti-resorptive or bone anabolic drug therapy in the previous 180-days\n* Acute use (\\>5-days) of any opioids (e.g., oxycodone, hydrocodone, etc) or systemic glucocorticoids \\>7.5 mg\u002Fd prednisone equivalent (e.g., hydrocortisone 30 mg, methylprednisolone 6 mg, or dexamethasone 1.2 mg) within 1-week before screening visit, except men who are taking these medications for a chronic condition and are anticipated to continue treatment for the study duration\n* Known allergy to any component of the TRT formulation (e.g., sesame oil or cottonseed oil)\n* Any other condition, therapy, lab abnormality, medical or psychiatric conditions, or reason that might pose a risk to the participant, make participation not in the person's best interest, confound the study results (e.g., inability to comply with study requirements), make the participant unsuitable to receive study intervention, or interfere with the person's ability to participate for the entire study duration","MALE",{"count":513,"type":21},21,[411],"This pilot study will determine the feasibility of implementing a combinatory rehabilitation strategy involving testosterone replacement therapy (TRT) with locomotor training (LT; walking on a treadmill with assistance and overground walking) in men with testosterone deficiency and walking dysfunction after incomplete or complete spinal cord injury. The investigators hypothesize that LT+TRT treatment will improve muscle size and bone mineral density in men with low T and ambulatory dysfunction after incomplete or complete SCI, along with muscle fundtion and walking recovery in men with T low and ambulatory dysfunction ater incomplete SCI.",[207,205,517,518,519,520,521,522,523,524,525,526,527,26,528,529,530,531,532,533],"Trauma, Nervous System","Wounds and Injury","Central Nervous System Diseases","Spinal Cord Diseases","Gonadal Disorders","Endocrine System Diseases","Hypogonadism","Genital Diseases, Male","Spinal Cord Trauma","Injuries, Spinal Cord","Walking, Difficulty","Locomotion Disorder, Neurologic","Wounds and Injuries","Nervous System Diseases","Testosterone Deficiency","Androgen Deficiency","Hormone Deficiency",[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,214,561,562,563,564,207],"Testosterone","Testosterone enanthate","Testosterone undecanoate","Testosterone 17 beta-cypionate","Methyltestosterone","Androgens","Hormones","Hormone Substitutes, and Hormone Antagonists","Physiologic Effects of Drugs","Pharmacologic Actions","Therapeutic Uses","Anabolic Agents","Testosterone Replacement Therapy","Dual Energy X ray Absorptiometry","Lean Tissue Mass","Body Composition","Muscle Strength","Muscle Mass","Bone Mineral Density","Adipose Tissue","Body Fat","Density, Bone","Bone Formation","Bone Resorption","Bone Density Conservation Agents","Magnetic Resonance Imaging","Ambulation","Locomotor","Locomotion","Treadmill","2025-05-01",{"date":567,"type":34},"2025-05-06",{"date":569,"type":34},"2021-01-31",{"date":267,"type":21},{"name":572,"class":41},"North Florida Foundation for Research and Education",{"id":574,"slug":575,"hasResults":11,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":11,"sex":16,"minAge":580,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":118,"phases":583,"briefSummary":584,"conditions":585,"keywords":586,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":42},"100550123","analyzing-gait-pattern-using-insole-type-gait-analyzer-in-patient-with-gait-disturbance-100550123","NCT06442982","Analyzing Gait Pattern Using Insole-type Gait Analyzer in Patient With Gait Disturbance","Usefulness of Insole-type Gait Analyzer in Collecting Gait Data From Patients With Gait Disturbance","Inclusion Criteria:\n\n1. adults aged 19 and over (based on the age on their national ID at the time of consent)\n2. adults complaining subjective gait or balance disorders\n3. individuals who voluntarily agree to participate in the study and sign a consent form\n\nExclusion Criteria:\n\n1. individuals unable to walk independently on flat ground for more than 6 minutes\n2. individuals who cannot read ordinary print with glasses due to visual reasons\n3. individuals who cannot understand conversation even with a hearing aid due to auditory reasons\n4. individuals with clinically significant disorders in the cardiovascular, gastrointestinal, respiratory, or endocrine systems\n5. individuals considered clinically unsuitable for the trial by the trial manager or person in charge based on significant medical findings.","19 Years",{"count":582,"type":21},600,[120],"The goal of this clinical trial is to explore the usefulness of information from insole-type gait analyzer in adults with subjective gait and balance disorders.\n\nThe main questions it aims to answer are:\n\nHow useful is an insole-type gait analyzer for collecting gait data from patients with gait disturbances?\n\nResearchers will explore the usefulness of collected data and does not establish a control group.\n\nParticipants will:\n\nParticipants will conduct survey and perform the Timed up and go test wearing an insole-type gait analyzer.",[26],[587,588,589],"gait analysis","smart insole","neurologic disorder","2025-02-05",{"date":592,"type":34},"2025-02-10",{"date":594,"type":34},"2021-06-01",{"date":596,"type":21},"2025-05-31",{"name":598,"class":41},"Yonsei University",{"id":600,"slug":601,"hasResults":11,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":11,"sex":16,"minAge":606,"maxAge":51,"enrollmentInfo":607,"targetDuration":4,"studyType":118,"phases":608,"briefSummary":609,"conditions":610,"keywords":611,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":42},"100551579","home-based-gait-rehabilitation-service-using-the-insole-type-gait-analysis-device-for-children-with-cerebral-palsy-100551579","NCT06461923","Home-based Gait Rehabilitation Service Using the Insole-type Gait Analysis Device for Children With Cerebral Palsy","Development and Feasibility Study of the Home-based Gait Rehabilitation Service by Using the Insole-type Gait Analysis Device for Children With Cerebral Palsy","Inclusion Criteria:\n\n1. Patients diagnosed with cerebral palsy aged 7 to 18 years old\n2. Patients classified as Gross Motor Function Classification System level 1 or 2\n3. Individuals who visited Severance Hospital, comprehended the study, agreed to participate, and submitted the informed consent form\n\nExclusion Criteria:\n\n1. Individuals with complications such as severe foot deformities where the sensors of the insole gait analysis device cannot be recognized\n2. In addition to above, individuals with clinically significant findings deemed inappropriate for this study by the study director or person in charge based on medical judgment","7 Years",{"count":338,"type":21},[120],"Walking is a crucial daily activity that requires complex coordination of muscular systems. It is essential for bone and muscle health, cardiovascular fitness, and activities of daily living, making it an important indicator of prognosis and patient function. Insole gait analysis devices are affordable and easy to use, and they align well with standardized 3D gait analysis. However, their use outside of hospital settings is limited.\n\nThis study aims to assess the usability and satisfaction of utilizing insole gait analysis devices for monitoring and providing feedback on the walking status of children with cerebral palsy exhibiting walking impairments in a home environment. Additionally, adherence to a home-based exercise program developed in this study will be evaluated.",[26,25],[612,588,613,614,420],"gait parameters","home-based exercise","monitoring system",{"date":592,"type":34},{"date":617,"type":34},"2024-08-01",{"date":619,"type":21},"2025-06",{"name":598,"class":41},{"id":622,"slug":623,"hasResults":11,"nctId":624,"briefTitle":625,"officialTitle":625,"acronym":4,"eligibilityCriteria":626,"healthyVolunteers":627,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":628,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":630,"conditions":631,"keywords":632,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":42},"100502270","investigating-neural-biomarkers-for-gait-in-parkinsons-patients-100502270","NCT05820074","Investigating Neural Biomarkers for Gait in Parkinson's Patients","Inclusion Criteria:\n\nAll participants\n\n* must have given informed consent as documented by signature\n* agree to comply with the study procedures\n\nHealthy control group\n\n* no neurological, orthopedic, or rheumatologic disease history\n* no identified sensory impairment.\n* no epilepsy and self-diagnosed acute or chronic psychiatric disorders\n\nParkinson's Patients\n\n* non-tremor dominant idiopathic PD patients\n* presence of postural instability (UPDRS \\>1 for postural instability \\[17\\]), gait disturbance, and absence of other causes of reduced balance\n* Implanted with Percept™ PC neurostimulator\n* Able to be in the stimulation OFF\n\nExclusion Criteria:\n\n* Relevant cognitive impairment, with a score on Montréal Cognitive Assessment (MoCA) \\\u003C 20\n* History of physical or neurological condition that interferes with study procedures\n* Social and\u002For personal circumstances interfering with the ability to come to the session",true,{"count":629,"type":21},60,"This observational study's main goal is to learn more about the neural mechanisms during movement in Parkinson's disease. Furthermore, it aims to inspire personalised treatment options.\n\nParticipants will undergo a protocol that involves walking and gait-related motor tasks, such as seated stepping. During the protocol, brain activity will be recorded.",[488,26],[633,612,634,635,636],"Parkinson's disease","neural activity","Percept PC","deep brain stimulation","2024-11-28",{"date":639,"type":34},"2024-12-03",{"date":641,"type":34},"2023-04-13",{"date":643,"type":21},"2025-03",{"name":645,"class":41},"Swiss Federal Institute of Technology",{"id":647,"slug":648,"hasResults":11,"nctId":649,"briefTitle":650,"officialTitle":650,"acronym":651,"eligibilityCriteria":652,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":653,"targetDuration":4,"studyType":118,"phases":654,"briefSummary":655,"conditions":656,"keywords":661,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":42},"100557504","adherence-to-long-term-exoskeleton-rehabilitation-to-treat-lower-limb-weakness-and--or-deficiencies-in-adult-population-100557504","NCT06538974","Adherence to Long-term Exoskeleton Rehabilitation to Treat Lower Limb Weakness and \u002F or Deficiencies in Adult Population","ALERT","Inclusion Criteria:\n\n* Patient suffering from lower limb weaknesses and \u002F or deficiencies regardless of the cause\n* Adult patient ≥18 years old\n* Patient able to read and write in French and who have signed an informed consent form\n* Patient affiliated to a social security system.\n\nExclusion Criteria:\n\n* Individual with severe spasticity of adductor muscles, hamstring, quadriceps and triceps surae. Severe spasticity is defined by a score of 4 on the modified Ashworth scale\n* Pregnant woman\n* Individual with history of osteoporotic fracture and \u002F or pathology or treatment causing secondary osteoporosis\n* Pressure Ulcer of Grade I or higher according to the NPUAP International Pressure Ulcer Classification System- EPUAP, in areas of contact with the Atalante X system\n* Severe aphasia limiting ability to express needs or to fulfil questionnaires, at the discretion of the physician.\n* Patient with a cardiac or respiratory contraindication to physical exertion, at discretion of the physician\n* Patient unable to deliver his\u002Fher consent\n* Patient under legal protection\n* Patient participating at the same time in another study\n* Patients with morphological contraindications to the use of the Atalante X exoskeleton (as per user's manual) with exceptions as follows: knee flessum of 20° authorized if sensibility is present; equinus of the ankle of 20° allowed regardless of presence or absence of sensibility, hip flessum of 20° allowed regardless of presence or absence of sensibility.",{"count":89,"type":21},[120],"In 2019, approximately 2.4 billion people worldwide required rehabilitation for various health pathologies, a 63% increase since 1990. It has been suggested that current rehabilitation frameworks (inpatient, outpatient, and community-based) are insufficient to meet local population needs due to issues like long waiting times, lack of facilities, prioritization, funding, and accessibility.Patients with lower limb weaknesses, resulting from various conditions (for example stroke, traumatic brain injury, spinal cord injury and others) require long-term management and motivation for engagement, which are crucial for functional outcomes. This highlights the need for sustainable gait and balance rehabilitation.\n\nNew technologies like exoskeletons have shown promising results in short-term inpatient programs, improving gait, balance, and quality of life, however, long-term follow-up data are still needed.\n\nThe present clinical investigation is a national, prospective, open-label interventional trial, proposing a 12-month outpatient rehabilitation program with the Atalante X exoskeleton to treat lower limb weakness and\u002For impairments in 100 participants. The rehabilitation program consists of at least one exoskeleton rehabilitation session per week. At the end of the first-year experimental phase, participants can continue for an additional year in the voluntary phase. The program aims to explore the potential long-term effects of supervised robotic rehabilitation on motor, cognitive, bowel, bladder functions, quality of life, and well-being. Assessments are conducted at baseline, after 4 and 12 months of exoskeleton rehabilitation, and at 16 and 24 months for participants in the voluntary phase.",[657,26,658,205,659,660],"Motor Disorders","Neurodegenerative Diseases","Weakness, Muscle","Cerebrovascular Accident",[662,663,66,65,96],"Hands-free Exoskeleton","Atalante X","2024-07-31",{"date":666,"type":34},"2024-08-06",{"date":668,"type":34},"2023-02-16",{"date":670,"type":21},"2027-07-02",{"name":672,"class":229},"Wandercraft",{"id":674,"slug":675,"hasResults":11,"nctId":676,"briefTitle":677,"officialTitle":677,"acronym":4,"eligibilityCriteria":678,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":679,"enrollmentInfo":680,"targetDuration":4,"studyType":118,"phases":681,"briefSummary":682,"conditions":683,"keywords":4,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":686,"lastUpdatePostDateStruct":687,"startDateStruct":689,"completionDateStruct":691,"leadSponsor":693,"locationsCount":4},"100328479","walking-ankle-robot-for-foot-drop-in-aging-and-disabled-populations-a-demonstration-project-100328479","NCT03556709","Walking Ankle Robot for Foot Drop in Aging and Disabled Populations: A Demonstration Project","Inclusion Criteria:\n\n1. Men and women, aged 18 to 88 years\n2. Chronic foot drop and ankle weakness in one leg from a peripheral nervous system injury due to a neuromuscular or orthopedic injury\n3. Ability to walk 10 meters and arise from a chair with no human assistance (but usage of usual assistive device\\[s\\] is permitted)\n\nExclusion Criteria:\n\n1. Cardiac history of (a) unstable angina; (b) recent (less than 3 months) myocardial infarction, congestive heart failure (NYHA category II); and\u002For (c) hemodynamically significant valvular dysfunction\n2. Hypertension that is a contraindication for a bout of walking training (greater than 160\u002F100 mmHg on two assessments)\n3. Medical history of (a) recent hospitalization (less than 3 months) for severe medical disease; (b) symptomatic peripheral arterial occlusive disease; (c) orthopedic or chronic pain conditions that significantly alter gait function; (d) pulmonary or renal failure; and\u002For (e) active cancer\n4. Current participation in orthopedic or rehabilitation medical programs\n5. Active deep venous thrombosis\n6. Distal paretic leg skin lesions, infections, or soft tissue inflammation","88 Years",{"count":89,"type":21},[120],"The purpose of this research study is to test the utility of an ankle robot, when used during treadmill walking, in people with ankle weakness and foot drop from a peripheral nervous system injury due to neuromuscular or orthopedic injury.",[684,685,26,159],"Foot Drop","Peripheral Nervous System Diseases","2018-06-04",{"date":688,"type":34},"2018-06-14",{"date":690,"type":21},"2018-08-01",{"date":692,"type":21},"2028-12-31",{"name":694,"class":695},"Baltimore VA Medical Center","FED",{"id":697,"slug":698,"hasResults":11,"nctId":699,"briefTitle":700,"officialTitle":700,"acronym":4,"eligibilityCriteria":701,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":679,"enrollmentInfo":702,"targetDuration":4,"studyType":118,"phases":703,"briefSummary":704,"conditions":705,"keywords":4,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":706,"lastUpdatePostDateStruct":707,"startDateStruct":709,"completionDateStruct":711,"leadSponsor":712,"locationsCount":42},"100326481","seated-ankle-robot-for-foot-drop-in-aging-and-disabled-populations-a-demonstration-project-100326481","NCT03530592","Seated Ankle Robot for Foot Drop in Aging and Disabled Populations: A Demonstration Project","Inclusion Criteria:\n\n1. Men and women, aged 18 to 88 years\n2. Chronic foot drop and ankle weakness in one leg from a peripheral nervous system injury due to a neuromuscular or orthopedic injury\n3. Ability to walk 10 meters and arise from a chair with no human assistance (but usage of usual assistive device\\[s\\] is permitted)\n\nExclusion Criteria:\n\n1. Medical history that would preclude participation in low-intensity seated robotic-assisted rehabilitation\n2. Current participation in orthopedic or rehabilitation medical programs\n3. Active deep venous thrombosis\n4. Distal paretic leg skin lesions, infections, or soft tissue inflammation",{"count":89,"type":21},[120],"The purpose of this research study is to test the utility of an ankle robot in people with ankle weakness and foot drop from a peripheral nervous system injury due to neuromuscular or orthopedic injury.",[685,26,684,159],"2018-05-08",{"date":708,"type":34},"2018-05-21",{"date":710,"type":21},"2018-06-01",{"date":692,"type":21},{"name":694,"class":695}]